Nasal therapy—The missing link in optimising strategies to improve prevention and treatment of COVID-19
Open Access
- 24 November 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 17 (11), e1010079
- https://doi.org/10.1371/journal.ppat.1010079
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- SARS-CoV-2 vaccines in developmentNature, 2020
- The coronavirus is mutating — does it matter?Nature, 2020
- A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2Cell, 2020
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory TractCell, 2020
- Iota-Carrageenan as an Antiviral Treatment for the Common ColdThe Open Virology Journal, 2020
- SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genesNature Medicine, 2020
- Developing Biodegradable Nanoparticles Loaded with Mometasone Furoate for Potential Nasal Drug DeliveryACS Omega, 2020
- Dendrimers as Drugs: Discovery and Preclinical and Clinical Development of Dendrimer-Based Microbicides for HIV and STI PreventionMolecular Pharmaceutics, 2005
- Studies of the basis of localization of influenza virus in ferret organ cultures.1972